Federal health and agriculture agencies have never formally assessed the biosecurity risks that come with selling laboratory equipment, according to a government watchdog report covered by The Washington Times.

The finding places two departments — Health and Human Services (HHS) and the Department of Agriculture (USDA) — on record as lacking any completed evaluation of what happens to surplus or decommissioned lab hardware once it leaves government custody and enters the resale market.

For R&D managers, the report touches a question that rarely appears on procurement checklists: what does an instrument carry with it when it walks out the door? Centrifuges, biosafety cabinets, freezers and other wet-lab gear can retain biological residue, and the secondary market for used laboratory equipment is large, liquid and largely unmonitored. The report indicates neither HHS nor USDA has weighed whether that resale channel constitutes a meaningful pathway for harmful agents or materials to reach unvetted buyers.

The gap matters because both departments operate high-containment laboratories. USDA runs facilities handling animal pathogens; HHS oversees a portfolio that includes work on select agents. Equipment cycled out of such environments typically moves through surplus-property disposal, auction platforms or specialized resellers. Without an agency-level risk assessment, disposal decisions default to individual labs and property officers applying their own judgment — an approach that produces inconsistent outcomes across sites.

The watchdog's conclusion, as reported by The Washington Times, is procedural rather than incident-driven: the failure is one of assessment, not of a documented breach. No specific case of misuse tied to resold federal lab equipment appears in the coverage. That distinction matters for readers calibrating actual exposure. The report establishes that the analytical work has not been done, not that it was done and produced reassuring results.

For university and institute administrators, the finding has a practical edge. Federal grant recipients and federal facilities often follow government disposal precedents, and a formal HHS or USDA risk framework — if one is eventually produced — would likely set decontamination, documentation and buyer-screening expectations that cascade to contractors and grantees. Labs planning equipment turnover in the next budget cycle may want to track whether agencies respond with new disposition rules before surplus sales are executed.

The report also lands at a moment of broader federal attention to laboratory biosafety. Oversight of high-containment research, pathogen inventory controls and dual-use research has drawn congressional scrutiny in recent sessions, and equipment disposition sits squarely inside that policy space. An unassessed resale pathway is the kind of exposure that tends to attract legislative attention once documented by a watchdog body.

What remains unknown from the available coverage is the scope of equipment sales at issue — dollar volumes, the number of federal labs involved, and whether any inventory exists of what has already been sold. The report's core contribution is identifying the assessment void itself.

The Washington Times coverage suggests the logical next step: both departments will face pressure to conduct the missing risk analysis and report back on whether current disposal practices warrant tighter controls on who can buy government lab hardware — and in what condition it leaves the building.